Evidence map›Paper›PMID 35749568›Full record

ArticlePLoS neglected tropical diseases2022

Impaired in vitro Interferon-γ production in patients with visceral leishmaniasis is improved by inhibition of PD1/PDL-1 ligation.

Yegnasew Takele, Emebet Adem, Susanne Ursula Franssen, Rebecca Womersley, Myrsini Kaforou, Michael Levin, Ingrid Müller, James Anthony Cotton, Pascale Kropf

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. PD-L1Frontiers in immunology · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Interferon-Science (New York, N.Y.) · 2024
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Yegnasew TakeleDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Emebet AdemLeishmaniasis Research and Treatment Centre, University of Gondar, Gondar, Ethiopia.
Susanne Ursula FranssenWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
Rebecca WomersleyDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Myrsini KaforouDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Michael LevinDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Ingrid MüllerDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
James Anthony CottonWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
Pascale KropfDepartment of Infectious Disease, Imperial College London, London, United Kingdom.ORCID 0000-0002-1670-8332
Imperial College London · GBWellcome Sanger Institute · GBUniversity of Gondar · ET

Funding

Wellcome Trust 204797/Z/16/ZWellcome Trust 206194Wellcome Trust 206508/Z/17/Z
6 · The paper itself

Abstract

Visceral leishmaniasis (VL) is a neglected tropical disease that causes substantial morbidity and mortality and is a growing health problem in Ethiopia, where this study took place. Most individuals infected with Leishmania donovani parasites will stay asymptomatic, but some develop VL that, if left untreated, is almost always fatal. This stage of the disease is associated with a profound immunosuppression, characterised by impaired production of Interferonγ (IFNγ), a cytokine that plays a key role in the control of Leishmania parasites, and high expression levels of an inhibitory receptor, programmed cell death 1 (PD1) on CD4+ T cells. Here, we tested the contribution of the interaction between the immune checkpoint PD1 and its ligand PDL-1 on the impaired production of IFNγ in VL patients. Our results show that in the blood of VL patients, not only CD4+, but also CD8+ T cells express high levels of PD1 at the time of VL diagnosis. Next, we identified PDL-1 expression on different monocyte subsets and neutrophils and show that PDL-1 levels were significantly increased in VL patients. PD1/PDL-1 inhibition resulted in significantly increased production of IFNγ, suggesting that therapy using immune checkpoint inhibitors might improve disease control in these patients.

Indexed as

Leishmania donovaniLeishmaniasis, VisceralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesHumansInterferon-gammaInterferon-gamma

Identifiers

PMID35749568
PMCPMC9262188
OpenAlexW4283371780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.